Precision Dosing of Alemtuzumab

Summary

The purpose of this study is to conduct a pilot trial of a Precision Dosing approach to alemtuzumab dosing for allogeneic hematopoietic cell transplantation of patients with non-malignant diseases. The investigators will measure the ability to use a population PK model of alemtuzumab to target patient Day 0 alemtuzumab levels to 0.15-0.6ug/mL in a pilot study of 20 patients.

Timeline

Start

2017-10-05

Primary completion

2019-03-10

Completion

2019-03-10

Drugs

Indications